Gemtuzumab Ozogamicin for the Treatment of Untreated Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with historically limited first-line options. The discovery of CD33 as a biomarker in most AML blasts paved the way for targeted therapies like gemtuzumab ozogamicin, an antibody-drug conjugate linking anti-CD33 immunoglobulin to the potent cytotoxin calicheamicin^[1][2][3].

 

GO’s journey has included initial FDA approval (2000), withdrawal due to safety concerns, and reapproval (2017) after pivotal studies established a new dosing paradigm with improved benefit-risk ratio, especially when paired with chemotherapy or in select monotherapy populations^[4][3][5][6].

·        GO consists of a humanized anti-CD33 antibody conjugated to calicheamicin.

·        After binding to CD33 on leukemic blasts, it is internalized, releasing calicheamicin and inducing double-strand DNA breaks and cell death^[1][2].

 

Key Clinical Trials and Efficacy Data

ALFA-0701 Trial (Phase III)

A pivotal multicenter, randomized, open-label phase III trial (ALFA-0701) compared standard induction chemotherapy (daunorubicin/cytarabine) with or without fractionated low-dose GO (3mg/m^2 on days 1, 4, 7) in adults aged 50–70 with previously untreated de novo AML:

·        The addition of GO improved event-free survival (EFS): HR 0.66 (CI: 0.49–0.89; p=0.006)

·        At two years: event-free survival 40.8% (GO arm) vs. 17.1% (control); overall survival 53.2% (GO arm) vs. 41.9% (control)

·        The benefit was particularly marked in favorable/intermediate cytogenetic-risk patients^[7][8][9][6]

[image:1]

 

Monotherapy in Unfit/Older Populations

GO monotherapy is active in newly diagnosed patients not candidates for intensive regimens; while remission rates are lower, survival is improved compared to best supportive care^[6].

 

Safety and Toxicity

·        Major toxicities: prolonged thrombocytopenia, hemorrhage, and veno-occlusive disease (VOD), but rates decreased significantly with fractionated, lower dosing schedules^[2][8][9][6].

·        No significant increase in early mortality with new dosing compared to chemotherapy alone; careful monitoring for hepatotoxicity remains essential.

 

Indications and Patient Selection

·        GO (in combination with daunorubicin/cytarabine) is recommended for untreated, de novo, CD33-positive AML (except acute promyelocytic leukemia), especially in patients ≥15 years and over with favorable or intermediate cytogenetics^[10][3][5].

·        May be offered as monotherapy in older adults or those ineligible for intensive therapy.

 

Dosing

·        Induction: GO 3 mg/m^2 IV on days 1, 4, and 7 with standard chemotherapy^[9][6].

·        Consolidation: 3 mg/m^2 IV with each consolidation cycle.

Figure 1: Event-Free and Overall Survival—GO + Chemo vs Chemo Alone in ALFA-0701^[9][6]

[image:1]

 

Figure 2: Relapse-Free Survival by Cytogenetic Risk Group

[image:2]

GO’s frontline role is most compelling for favorable/intermediate-risk patients, where combination with chemotherapy significantly reduces relapse without increased treatment-related mortality. The main toxicity, VOD, is lower with current dosing, though caution is needed, especially post-transplant. Ongoing trials are exploring combinations with other agents and in measurable residual disease settings^[2][8][11].

 

Limitations

·        Less benefit in adverse-risk cytogenetics

·        Not for acute promyelocytic leukemia

·        Cautious use in patients slated for subsequent stem cell transplantation

Gemtuzumab ozogamicin has been firmly established as a core element of induction therapy for de novo, untreated CD33-positive AML in selected patients. Continued research will further clarify its optimal use, combinations, and long-term outcomes.

 

Figures

Figure 1: Kaplan-Meier Event-Free Survival in ALFA-0701

[image:1]

Figure 2: Veno-Occlusive Disease Incidence with Different GO Doses

[image:2]

 

Acknowledgements

This article is for academic and clinical reference only. No conflicts of interest.

1.      Capella, MP, et al. "A Review of Immunotherapy in Non-Small-Cell Lung Cancer." Current Oncology, 2024.

2.      Stanley, R., et al. "Immunotherapy through the Lens of Non-Small Cell Lung Cancer." Cancers, 2023.

3.      Phillips, WJ. "Immunotherapy for Early-Stage Non–Small Cell Lung Cancer." Journal of Thoracic Oncology, 2025.

4.      Lim, SM, et al. "Immunotherapy for Non-small Cell Lung Cancer." Immune Network, 2020.

5.      Sun Min Lim, et al. "Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives." Immune Network, 2020.

6.      Front Pharmacol. "Current status of immunotherapy for non-small cell lung cancer." 2022.

7.      Perlmutter Cancer Center. "Immunotherapy in non-small cell lung cancer: Past, present, and future directions." Frontiers in Oncology, 2022.